Sector News

Ashland to sell nutraceuticals business to Turnspire Capital Partners

May 11, 2024
Life sciences

US specialty chemicals producer Ashland has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. Financial details of the transaction were not given.

Ashland’s nutraceuticals business, the company stated, supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies, as well as custom formulation and contract manufacturing capabilities for the nutrition market, from four production facilities in New Jersey and Utah in the US, and Tamaulipas, Mexico.

“The nutraceuticals business has a strong portfolio of proprietary ingredients, formulation and manufacturing capabilities, and a dedicated team that has demonstrated a passion to grow over the years,” said Guillermo Novo, CEO of Ashland.

On the occasion of an update on the company’s fiscal 2023 fourth-quarter and full-year earnings on Nov. 1, 2023, Ashland announced its plan to initiate portfolio-optimization actions to further strengthen its resilience and improve profitability. One of these actions was the start of a divestiture process for the company’s nutraceuticals business.

comments closed

Related News

May 17, 2024

With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide

Life sciences

Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.

May 17, 2024

Sanofi invests €1 Billion to boost drug manufacturing in France

Life sciences

The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.

May 17, 2024

Lonza, busy with capacity upgrades and exec turnover, hints at CDMO industry rebound

Life sciences

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.

How can we help you?

We're easy to reach